Central Nervous System Prophylaxis Approach in High‐Risk Diffuse Large B‐Cell Lymphoma Patients: A Retrospectively Collected, Single‐Center Cohort Analysis
Owing to the lack of robust evidence, the role of HD-MTX in preventing CNS recurrence could not be conclusively determined. Nevertheless, some patients could tolerate the treatment, such as younger individuals and those at NCCN-IPI low or intermediate risk, suggesting the efficacy of intravenous HD-MTX administration on day 6 as an optimal strategy for preventing CNS recurrence of DLBCL.
Authors
- Hongwei Zhang (ORCID: https://orcid.org/0000-0002-6819-5225)
- Liping Su
- Tao Guan
- Weie Han
- Yanli Wang (ORCID: https://orcid.org/0000-0001-7689-722X)
- Min Zhang (ORCID: https://orcid.org/0000-0003-4506-8212)
- Xiaolan Liu (ORCID: https://orcid.org/0000-0002-3819-6198)
- Xiaolian Wen
- Weihua Zhang (ORCID: https://orcid.org/0000-0003-2406-0852)
- Min Bai (ORCID: https://orcid.org/0000-0003-3905-0470)
Institutions
- Shanxi Medical University (CN)
- Shanxi Provincial Cancer Hospital (CN)
- First Hospital of Shanxi Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70830
- Citations
- 1
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Beijing Xisike Clinical Oncology Research Foundation